These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15566321)

  • 1. Cancer immunotherapeutics meeting.
    Slovin SF
    Expert Opin Investig Drugs; 2004 Dec; 13(12):1645-50. PubMed ID: 15566321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summary of the primer on tumor immunology and the biological therapy of cancer.
    Li Y; Liu S; Margolin K; Hwu P
    J Transl Med; 2009 Jan; 7():11. PubMed ID: 19175928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology Keystone Symposia Meeting Summary.
    Gubin MM
    Cancer Immunol Res; 2017 Jun; 5(6):434-438. PubMed ID: 28576922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Immunotherapeutics and Vaccine Summit - CHI's fifth annual meeting - novel vaccines: adjuvants and delivery systems: part 1.
    Jones SD
    IDrugs; 2010 Oct; 13(10):689-91. PubMed ID: 20878588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 16th Annual Scientific Meeting of the Society for Biological Therapy. 8 - 11 November 2001, Bethesda, Maryland, USA.
    Dillman RO; Dillman JB
    Expert Opin Biol Ther; 2002 Feb; 2(2):223-7. PubMed ID: 12170947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conference scene--active immunotherapeutics forum: meeting highlights.
    Lisziewicz J
    Immunotherapy; 2009 Sep; 1(5):743-8. PubMed ID: 20636019
    [No Abstract]   [Full Text] [Related]  

  • 7. The Immunotherapeutics and Vaccine Summit - CHI's fifth annual meeting - novel vaccines: adjuvants and delivery systems: part 2.
    Jones SD
    IDrugs; 2010 Oct; 13(10):692-4. PubMed ID: 20878589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer. 30 October-2 November 2003, Bethesda, Maryland, USA.
    Marincola FM; Wang E; Atkins MB
    Expert Opin Biol Ther; 2004 Jan; 4(1):107-14. PubMed ID: 14680473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.
    Butt AQ; Mills KH
    Oncogene; 2014 Sep; 33(38):4623-31. PubMed ID: 24141774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting.
    De Santis F; Del Vecchio M; Castagnoli L; De Braud F; Di Cosimo S; Franceschini D; Fucà G; Hiscott J; Malmberg KJ; McGranahan N; Pietrantonio F; Rivoltini L; Sangaletti S; Tagliabue E; Tripodo C; Vernieri C; Zitvogel L; Pupa SM; Di Nicola M
    Cytokine Growth Factor Rev; 2018 Dec; 44():1-10. PubMed ID: 30393044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proceedings of the joint meeting of the 8th Annual Meeting of the Society of Biotherapeutic Approaches and the 3rd Meeting of the Japan Research Association of Immunotherapeutics. December 4, 2004. Fukuoka, Japan.
    Anticancer Res; 2005; 25(6A):3679-776. PubMed ID: 16323359
    [No Abstract]   [Full Text] [Related]  

  • 12. The 3rd International Conference on Cancer Vaccines/Adjuvants/Delivery for the Next Decade (CVADD): meeting highlights. 11-13 November, 2009, Dublin, Ireland.
    Umansky V
    Immunotherapy; 2010 Mar; 2(2):151-4. PubMed ID: 20635923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proceedings of the 7th Annual Meeting of the Society of Biotherapeutic Approaches and the 2nd Annual Meeting of the Japan Research Association for Immunotherapeutics. December 7, 2003. Tokyo, Japan.
    Anticancer Res; 2004; 24(5C):3289-392. PubMed ID: 15529466
    [No Abstract]   [Full Text] [Related]  

  • 14. Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives-a meeting report.
    Pinto C; Bergmann M; Briukhovetska D; Nuessler V; Sznol M; von Bergwelt-Baildon M; Kobold S
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspective: cancer vaccines in the era of immune checkpoint blockade.
    Cebon J
    Mamm Genome; 2018 Dec; 29(11-12):703-713. PubMed ID: 30446791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T Lymphocyte-Based Cancer Immunotherapeutics.
    Borrie AE; Maleki Vareki S
    Int Rev Cell Mol Biol; 2018; 341():201-276. PubMed ID: 30262033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conference scene: Immune signatures in the tumor and beyond.
    Kandalaft LE; Kalos M; Melief CJ; Speiser DE; Coukos G
    Immunotherapy; 2012 Aug; 4(8):761-72. PubMed ID: 22947003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. American Association for Cancer Research: Clinical trials of immunotherapeutics and immunologic monitoring. April 1-5, 2000, San Francisco, CA, USA.
    Salgaller ML
    Expert Opin Investig Drugs; 2000 Jun; 9(6):1413-7. PubMed ID: 11203450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conditioning neoadjuvant therapies for improved immunotherapy of cancer.
    Benson Z; Manjili SH; Habibi M; Guruli G; Toor AA; Payne KK; Manjili MH
    Biochem Pharmacol; 2017 Dec; 145():12-17. PubMed ID: 28803721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting.
    Miyahira AK; Kissick HT; Bishop JL; Takeda DY; Barbieri CE; Simons JW; Pienta KJ; Soule HR
    Prostate; 2015 Mar; 75(4):337-47. PubMed ID: 25358693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.